HSP90AA1 and malignant colon neoplasm: To examine the role of reactivation of ERK and Akt in resistance of mutant BRAF colon cancer cells to HSP90 inhibition, we treated RKO and WiDr cells with the MEK inhibitor AZD6244 or the PI3K inhibitor LY294002 before addition of AUY922.